Submitted: 08 Aug 2020
Accepted: 12 Sep 2020
ePublished: 29 Sep 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Endocrinol. 2021;7(1): e05.
  Abstract View: 225
  PDF Download: 83

Original Article

Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program

Anselmo Abdo-Cuza 1 * ORCID logo, Roberto Castellanos-Gutiérrez 1 ORCID logo, Janete Treto-Ramirez 1, Sandra Arencibia-Larin 1 ORCID logo, Thalía Gómez-Pariente 1, Tania González-Fernández 1, Julio C. Hernández-Perera 1 ORCID logo, Katia Arocha-Stalella 1, Niurka Verdecia-Gorrita 1, Lisy Vento-Buigues 1, Yanet Cordero-Vasallo 1 ORCID logo, Yusmel Rivero-Yi 1, Odalys González-Dias 2, Hugo Nodarse-Cuni 2, Rafael Machado-Martínez 1 ORCID logo, Miguel A. Blanco-González 1 ORCID logo, Julio Valdivia-Arencibia 1, Daymiris Mendez-Felipe 1, Ernesto Delgado-Almora 1, Carlos Gutiérrez-Gutiérrez 1, Juliette Suárez-López 3 ORCID logo, Jorge L. Leiva-Torres 1, Alicia Rodríguez-Sotolongo 1, Nilda Bejerano-Gil 1

1 Centro de Investigaciones Médico Quirúrgicas, La Habana, Cuba.
2 Centro de Ingeniería Genética y Biotecnología, La Habana, Cuba
3 Hospital Hermanos Ameijeiras. La Habana, Cuba
*Corresponding Author: Anselmo A. Abdo-Cuza, MD, PhD, Email: aaabdo@infomed.sld.cu

Abstract

Introduction: Patients diagnosed with end-stage chronic kidney disease on a hemodialysis program (HDP) represent a risk group for COVID-19. Scientific societies have developed guidelines for the prevention of contagion, but there is no prophylactic medicine in them.

Objectives: To describe the safety and efficacy of recombinant intranasal human Interferon alfa 2b as prophylaxis for COVID-19 in patients in an HDP.

Patients and Methods: Intervention description through the monitoring of 15 patients in outpatient HDP. Prior to the administration of the drug, clinical, radiological evaluation and hematology and blood chemistry studies were performed. Daily contact was made with each study patient in person or by telephone, asking about the occurrence of adverse events or symptoms of disease.

Results: In 47% of the patients, there was leukopenia, lymphopenia in 67% and anemia and thrombocytopenia in 33% respectively, prior to the use of the drug. There was no clinical suspicion of COVID-19 in any of them. Adverse events occurred in 3 patients (20%), all were mild and non-severe. All patients were negative for SARS-CoV-2 real-time polymerase chain reaction (rtPCR) and antibody studies 45 days after the study started.

Conclusion: the use of intranasal recombinant human interferon alfa 2b as prophylaxis of COVID-19 in patients in a HDP at a dose of 1 MIU daily for ten days, as part of a prevention protocol, has an adequate safety profile. None of the patients in the series was infected with SARS-CoV-2 during the surveillance period.

Keywords: Interferon type I, Coronavirus infections, COVID-19, Hemodialysis units hospital, SARS-CoV-2, Renal insufficiency chronic, Prevention & control
Citation: Abdo-Cuza A, Castellanos-Gutiérrez R, Treto-Ramirez J, Arencibia-Larin S, Gómez-Pariente T, González-Fernández T, HernándezPerera JC, Arocha-Stalella K, Verdecia-Gorrita N, Vento-Buigues L, Cordero-Vasallo Y, Rivero-Yi Y, González-Dias O, Nodarse-Cuni H, Machado-Martínez R, Blanco-González MA, Valdivia-Arencibia J, Mendez-Felipe D, Delgado-Almora E, Gutiérrez-Gutiérrez C, SuárezLópez J , Leiva-Torres JL, Rodríguez-Sotolongo A, Bejerano-Gil N. Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program. J Renal Endocrinol. 2021;7:e05.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 225

Your browser does not support the canvas element.


PDF Download: 83

Your browser does not support the canvas element.